๐ Q1 Shockwave! Thyrocare Delivers 64% PAT Surge – Analysts Predict ₹1,400 Target ๐จ 25.07.2025

Thyrocare Technologies: India’s Diagnostics Dynamo with ₹1,400 Target! ๐ (+16% Upside) ๐ข Q1FY26 Blowout Triggers Re-Rating Buzz India’s diagnostics market is heating up—and Thyrocare Technologies (NSE: THYROCAR) just threw gasoline on the fire. Its Q1FY26 earnings crushed Street estimates with 23% YoY revenue growth and a 400-bps jump in EBITDA margin . With volumes soaring and parent API Holdings scaling PharmEasy synergies , analysts now peg the stock’s fair value at ₹1,400 , implying 16% upside from current levels. Here’s why Thyrocare is rapidly emerging as a long-term compounder in healthcare diagnostics. ๐ 1. Q1FY26 Results: A Diagnostic Breakthrough ๐ Key Financial Highlights Revenue : ₹1,930 million, up 23% YoY (beat estimates by 3.3%) Volume Growth : +15% YoY in test/sample count Realization per Sample : +8% YoY (driven by premium and wellness test upsell) EBITDA Margin : Jumped to 33% (up 400 bps YoY) PAT : ₹442 million, +64% YoY (beat estimates by 42...